Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Ascorbic acid (Primary) ; Azithromycin (Primary) ; Hydroxychloroquine (Primary) ; Vitamin D (Primary) ; Zinc (Primary)
- Indications COVID 2019 infections; Respiratory tract infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms HAZCpaC
- 27 Feb 2024 Status changed from recruiting to completed.
- 08 Jun 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2024.
- 08 Jun 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2023.